Takayasu ArteritisTAK-IMPACTNCT07351422
Investigating Management, Perspectives and Attitudes Towards Care in Takayasu Arteritis
An observational study of Takayasu Arteritis and Takayasu Arteritis (TAK), run by University of Edinburgh at 1 site in United Kingdom.
Trial summary
This study aims to understand the experiences of patients with Takayasu arteritis (TAK) and how physicians manage the condition. To achieve this, two separate questionnaires will be conducted: one for patients and one for physicians. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Takayasu Arteritis, Takayasu Arteritis (TAK)
- What is being tested?
- Questionnaire
- How many people
- 50 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 1 Oct 2025to 15 Mar 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participants are UK-based
Who may be able to join
- For the patient questionnaire:
- Age ≥ 18 years
- A formal diagnosis of TAK
- For the physician questionnaire
- A physician involved in the management/decision-making for patients diagnosed with TAK
Who cannot join
- For the patient questionnaire:
- Age < 18 years
- Lack of a formal diagnosis of TAK
- Patients without mental capacity or willingness to provide informed consent
- Not UK based
- For the physician questionnaire
Show all 9Show fewer
- Not involved in the management/ decision making for patients diagnosed with TAK
- Not willing to take part
- Not UK based
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site, 1 recruiting
- Recruiting
University of Edinburgh
Edinburgh
Alexandra Armstrong, +44 7445695898, A.Armstrong-9@sms.ed.ac.uk
About this study
This study aims to understand the experiences of patients with Takayasu arteritis (TAK) and how physicians manage the condition. To achieve this, two separate questionnaires will be conducted: one for patients and one for physicians.
Read the detailed description
This study aims to investigate the experiences and perceptions of patients with Takayasu arteritis regarding their disease, as well as the perspectives of physicians regarding the management and treatment of these patients.
Patients with TAK will be invited to complete an anonymous online (Online Surveys) questionnaire, which will take approximately 25 minutes and will consist of multiple-choice and short-answer questions. The questionnaire will ask about their experience with the condition, symptoms, treatments they have received, and any concerns or priorities they have regarding their care.
Physicians who treat TAK will also be invited to complete a separate online questionnaire, taking around 15 minutes and also consisting of multiple-choice and short-answer questions. This will explore how they diagnose and manage TAK, their choice of treatments, and any challenges they face in treating the condition
- Conditions
- Takayasu Arteritis, Takayasu Arteritis (TAK)
- Being tested
- Questionnaire
- Medical subject headings
- Takayasu Arteritis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
QuestionnaireOther
An online annoymous questionnaire consisting of short-answer and multiple-choice questions
| Study group | Role | What they receive |
|---|---|---|
| Patients with Takayasu Arteritis | Not described Receives: Other: Questionnaire | |
| Physicians Involved in the Management of Patients with Takayasu Arteritis | Not described Receives: Other: Questionnaire |
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient Perspective
To understand the lived experiences of individuals with TAK, including their symptoms, health status post-diagnosis, treatment priorities, and concerns.
The questionnaire covers the following topics:
- Basic background information
- Living with Takayasu arteritis
- Changes to health since diagnosis
- Physical activity and exercise habits- measured by the International Physical Activity Questionnaire (IPAQ)
- Smoking history
- Mental well-being- measured by the EQ-5D instrument
- Nutrition and diet
- Personal views and priorities on management
Measured: Day 1
Physician Perspective
To evaluate current clinical management strategies for TAK, identify treatment priorities, and highlight areas of unmet need in clinical practice.
The physician questionnaire covers the following topics:
- Clinical background and experience with TAK patients
- Diagnostic and treatment strategies for TAK
- Consideration of cardiovascular disease risk in TAK management
- Physician priorities and unmet needs of management
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jan 2026
- Study start1 Oct 2025
- Primary completion15 Mar 2027 (estimated)
- Study completion15 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Takayasu ArteritisStudies of the same condition, open and under way.
- More trials run by University of EdinburghThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Edinburgh
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07351422
- Sponsor's protocol ID
- 25-EMREC-064
- Acronym
- TAK-IMPACT
- Status last verified
- Jan 2026
- First submitted
- 14 Nov 2025
- Last updated
- 20 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigating Management, Perspectives and Attitudes Towards Care in Takayasu Arteritis
- ClinicalTrials.gov ID
- NCT07351422
- Acronym / sponsor ID
- TAK-IMPACT / 25-EMREC-064
- Conditions
- Takayasu Arteritis, Takayasu Arteritis (TAK)
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- University of EdinburghUniversity, hospital or other
- Study start
- 1 Oct 2025 (actual)
- Primary completion
- 15 Mar 2027 (estimated)
- Study completion
- 15 Mar 2027 (estimated)
- First posted
- 20 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to understand the experiences of patients with Takayasu arteritis (TAK) and how physicians manage the condition. To achieve this, two separate questionnaires will be conducted: one for patients and one for physicians.
Detailed description
This study aims to investigate the experiences and perceptions of patients with Takayasu arteritis regarding their disease, as well as the perspectives of physicians regarding the management and treatment of these patients.
Patients with TAK will be invited to complete an anonymous online (Online Surveys) questionnaire, which will take approximately 25 minutes and will consist of multiple-choice and short-answer questions. The questionnaire will ask about their experience with the condition, symptoms, treatments they have received, and any concerns or priorities they have regarding their care.
Physicians who treat TAK will also be invited to complete a separate online questionnaire, taking around 15 minutes and also consisting of multiple-choice and short-answer questions. This will explore how they diagnose and manage TAK, their choice of treatments, and any challenges they face in treating the condition
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients with Takayasu Arteritis | – | Other: Questionnaire |
| Physicians Involved in the Management of Patients with Takayasu Arteritis | – | Other: Questionnaire |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Participants are UK-based
Key inclusion criteria (5 listed)
- Age ≥ 18 years
- A formal diagnosis of TAK
- For the physician questionnaire
- A physician involved in the management/decision-making for patients diagnosed with TAK
Key exclusion criteria (9 listed)
- Age < 18 years
- Lack of a formal diagnosis of TAK
- Patients without mental capacity or willingness to provide informed consent
- Not UK based
- For the physician questionnaire
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| QuestionnaireAn online annoymous questionnaire consisting of short-answer and multiple-choice questions | Other | Patients with Takayasu Arteritis, Physicians Involved in the Management of Patients with Takayasu Arteritis |
Primary outcome
Patient Perspective
Time frame: Day 1
To understand the lived experiences of individuals with TAK, including their symptoms, health status post-diagnosis, treatment priorities, and concerns. The questionnaire covers the following topics: * Basic background information * Living with Takayasu arteritis * Changes to health since diagnosis * Physical activity and exercise habits- measured by the International Physical Activity Questionnaire (IPAQ) * Smoking history * Mental well-being- measured by the EQ-5D instrument * Nutrition and diet * Personal views and priorities on management
Physician Perspective
Time frame: Day 1
To evaluate current clinical management strategies for TAK, identify treatment priorities, and highlight areas of unmet need in clinical practice. The physician questionnaire covers the following topics: * Clinical background and experience with TAK patients * Diagnostic and treatment strategies for TAK * Consideration of cardiovascular disease risk in TAK management * Physician priorities and unmet needs of management
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Takayasu Arteritis
RecruitingObservational study
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Takayasu's Arteritis, Giant Cell Arteritis
Not yet recruiting
Long-Axial Field of View (LAFOV) [18F]FDG PET/CT Imaging in Large Vessel Vasculitis (LVV): Protocol Optimisation Study.
Large Vessel Vasculitis, Takayasu Arteritis
RecruitingObservational study
Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement
Takayasu Arteritis With Pulmonary Artery Involvement, Percutaneous Transluminal Pulmonary Angioplasty
Not yet recruitingObservational study
Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research
Pericarditis, Tako-TSUBO Cardiomyopathy
RecruitingPhase 4
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Takayasu Arteritis and Takayasu Arteritis (TAK), run by University of Edinburgh at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Alexandra Armstrong (+447445695898, A.Armstrong-9@sms.ed.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient Perspective (time frame: Day 1). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jan 2026.